BMO Capital Markets Has Lowered Expectations for Disc Medicine (NASDAQ:IRON) Stock Price

Disc Medicine (NASDAQ:IRON) had its target price decreased by equities researchers at BMO Capital Markets from $120.00 to $100.00 in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage currently has an “outperform” rating on the stock. BMO Capital Markets’ target price suggests a potential upside of 55.09% from the company’s previous close.

Several other analysts have also issued reports on the stock. Morgan Stanley restated an “overweight” rating and issued a $120.00 price objective on shares of Disc Medicine in a report on Thursday, January 8th. Wedbush reissued an “outperform” rating on shares of Disc Medicine in a research note on Thursday, January 15th. UBS Group reaffirmed an “overweight” rating on shares of Disc Medicine in a research report on Thursday, January 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research note on Wednesday, January 21st. Finally, Raymond James Financial reiterated a “market perform” rating on shares of Disc Medicine in a research note on Thursday, January 15th. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.82.

Disc Medicine Stock Performance

NASDAQ:IRON opened at $64.48 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.45 and a current ratio of 23.45. The stock has a market capitalization of $2.43 billion, a PE ratio of -12.05 and a beta of 0.88. Disc Medicine has a fifty-two week low of $30.82 and a fifty-two week high of $99.50. The company has a fifty day moving average of $77.84 and a two-hundred day moving average of $75.21.

Insider Activity

In other news, insider Pamela Stephenson sold 5,531 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total value of $347,678.66. Following the transaction, the insider owned 80,998 shares of the company’s stock, valued at approximately $5,091,534.28. The trade was a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider William Jacob Savage sold 3,256 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total transaction of $204,672.16. Following the completion of the transaction, the insider directly owned 92,589 shares in the company, valued at $5,820,144.54. This represents a 3.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 273,605 shares of company stock worth $24,193,736 over the last quarter. 3.64% of the stock is owned by insiders.

Hedge Funds Weigh In On Disc Medicine

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its holdings in shares of Disc Medicine by 110.0% in the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock valued at $125,557,000 after purchasing an additional 828,248 shares during the last quarter. BVF Inc. IL purchased a new position in shares of Disc Medicine in the 4th quarter worth $51,616,000. Jennison Associates LLC acquired a new position in Disc Medicine in the fourth quarter valued at $42,252,000. Perceptive Advisors LLC purchased a new stake in Disc Medicine during the fourth quarter valued at about $35,794,000. Finally, RA Capital Management L.P. increased its stake in Disc Medicine by 25.3% during the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock worth $156,925,000 after acquiring an additional 399,026 shares during the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Disc Medicine

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Disc will pursue a traditional U.S. approval pathway for bitopertin after the FDA declined the new fast‑track route — this gives management a concrete regulatory path forward rather than abandoning the program. Read More.
• Positive Sentiment: Cantor Fitzgerald initiated/maintained a positive stance and Stifel Nicolaus stuck with a buy rating, which can support institutional demand despite headline volatility. Read More.
• Neutral Sentiment: Management hosted an investor discussion/transcript addressing the FDA Complete Response Letter — investors are parsing details on requested data, resubmission timeline and implications for ongoing trials (APOLLO). The call reduces information asymmetry but does not yet remove regulatory risk. Read More.
• Neutral Sentiment: Analyst commentary is mixed: some emphasize lingering regulatory risk and timing, while others point to upside if APOLLO or other data are favorable — expect divergent price targets and trading around trial news. Read More.
• Negative Sentiment: Reports indicate the FDA rejection was coupled with skepticism from external advisers, increasing the likelihood of additional data requests or delay for approval — a material near‑term negative for valuation. Read More.
• Negative Sentiment: Multiple insiders — including the CEO and other senior officers — disclosed sales of shares on Feb 17 (and a pattern of recent sales by some insiders), which the market often interprets as a negative signal about near‑term outlook. Read More.
• Negative Sentiment: Pomerantz LLP launched an investor investigation into Disc Medicine, introducing potential litigation risk and added headline pressure that can weigh on the stock until resolved. Read More.
• Negative Sentiment: Several firms trimmed price targets today (even where ratings stayed positive), reflecting a lower near‑term valuation baseline until regulatory clarity is restored. That likely cements downward pressure on the stock in the short term. Read More.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.